All relevant data are within the manuscript.

Introduction {#sec005}
============

Alzheimer's disease (AD), the most common type of dementia, is characterized by the extracellular accumulation of amyloid-β protein (Aβ) plaques and intraneuronal aggregates of hyperphosphorylated tau that form neurofibrillary tangles in the brain. AD develops in \~5% of individuals over 65 years of age and in about 20% of those over 85 years of age. Currently, AD affects 26 million people around the world, and by 2050 over 100 million are expected to be affected. \[[@pone.0236568.ref001]\] A rare, early-onset familial AD has also been reported. \[[@pone.0236568.ref002]\] A non-specific cognitive decline, referred to as mild cognitive impairment (MCI), may precede AD and is frequent in the elderly population. \[[@pone.0236568.ref003],[@pone.0236568.ref004]\] In addition, there are several recognized risk factors for AD, including diabetes, obesity and hypercholesterolemia. \[[@pone.0236568.ref005]\] The diagnosis of AD is currently made using a series of tests, beginning with questionnaires, such as the Mini-Mental State Examination, designed to assess the intellectual, emotional and functional status of the patient. \[[@pone.0236568.ref006]\] Second-level tests include positron emission tomography (PET), single photon emission computed tomography (SPECT), cerebrospinal fluid Aβ42 level measurement, and assessment of medial temporal lobe atrophy via brain magnetic resonance imaging (MRI). \[[@pone.0236568.ref007]\]

Worsening of visual function is a common feature of AD, \[[@pone.0236568.ref008]\] and the accumulation of Aβ plaques and aggregates of hyperphosphorylated tau in the visual association cortices, \[[@pone.0236568.ref009],[@pone.0236568.ref010]\] primary visual cortex, \[[@pone.0236568.ref011],[@pone.0236568.ref012]\] lateral geniculate nuclei, \[[@pone.0236568.ref013],[@pone.0236568.ref014]\] and the retina \[[@pone.0236568.ref015]--[@pone.0236568.ref017]\] has been reported. The visual disturbances in AD were long considered to be due to damage in the primary and associative visual cortex, but a primary involvement of retinal ganglion cells (RGCs) and their axons has also been proposed. \[[@pone.0236568.ref015],[@pone.0236568.ref018]--[@pone.0236568.ref019]\]

Furthermore, AD patients may suffer deficits in contrast sensitivity. \[[@pone.0236568.ref020]--[@pone.0236568.ref022]\]

The visual pathway is composed of two different systems. The magnocellular (M) system recognizes achromatic stimuli. It originates from large RGCs and projects first to the magnocellular layers of the lateral geniculate nucleus and then to lamina 4C-ɑ of the visual cortex. The second system is specific for color discrimination. It originates from small RGCs and projects first to the parvocellular layers of the lateral geniculate nucleus and then to lamina 4C-ß of the visual cortex. This system can be further divided in two different color-based pathways: the red-green parvocellular (P) and the blue-yellow koniocellular (K) subsystems. The M system responds to achromatic stimuli, and the P subsystem to chromatic stimuli but also to achromatic contrast stimuli of high spatial frequency. However, within the same range of spatial frequencies, M-cells are more sensitive to achromatic stimuli, especially at higher temporal frequencies. \[[@pone.0236568.ref023]\] Whether AD specifically affects one or the other sub/system is unclear. Pathologies in both the M system and the P subsystems have been described in the lateral geniculate nucleus and in the retina, \[[@pone.0236568.ref023]--[@pone.0236568.ref025]\] but other evidence suggests a specific M pathway involvement. \[[@pone.0236568.ref023],[@pone.0236568.ref025]--[@pone.0236568.ref028]\]VD is the second most common type of dementia worldwide, and its prevalence in individuals age 65 and older is expected to double every 5 years. \[[@pone.0236568.ref029]\] It leads to several cognitive disorders as well as behavioral and locomotor abnormalities. The most important cause of VD is cerebral small-vessel disease; other causes are cardiac and carotid atherosclerosis, cardioembolism, hypertensive vasculopathy, aneurysm, vascular malformations, amyloid angiopathies, monogenic disorders involving stroke as well as metabolic, hematological and vasospastic disorders. Although, like AD, a diagnosis of VD can be made with certainty only post-mortem, strong clinical suspicion is based on history, timing of the event, cardiovascular and hematological assessment, psychometric evaluation and neuroimaging features. \[[@pone.0236568.ref029]\]

In the evaluation of AD, neuroimaging techniques include structural MRI and PET (tracing amyloid, fluorodeoxyglucose, tau). The typical MRI features of AD are a reduction of gray-matter volume, cortical atrophy and a reduced hippocampal volume. Amyloid PET is recommended especially in patients with otherwise unexplained cognitive impairment or an atypical clinical presentation. Other types of PET are mainly used in clinical research. \[[@pone.0236568.ref030]\]

In VD, typical imaging features are white matter lesions, cortical and subcortical infarctions and intracerebral microhemorrhage. Extensive parenchymal infarctions are due to large-artery disease, and small infarctions especially to small-vessel disease. \[[@pone.0236568.ref029]\] In the eye, the primary involvement in AD patients is the RGCs \[[@pone.0236568.ref015]--[@pone.0236568.ref019]\] whereas the visual disturbances found in VD are often due to cerebral infarctions involving the optic pathway, leading to typical visual field alterations according to the affected site; retrogeniculate alterations do not determine subsequent optic atrophy \[[@pone.0236568.ref031]\] Primary involvement of the retina has also been documented in patients with cerebral autosomal arteriopathy with subcortical infarcts and leukoencephalopathy, \[[@pone.0236568.ref032]\] hereditary endotheliopathy with retinopathy, nephropathy and stroke, cerebroretinal vasculopathy and hereditary vascular retinopathy, which are interpreted as different phenotypes of the same disease, i.e., autosomal dominant retinal vasculopathy with cerebral leukodystrophy. \[[@pone.0236568.ref033]--[@pone.0236568.ref035]\] In all of these diseases, retinal damage is due to vascular retinopathy, not to primary neurodegeneration. Unlike other parts of the central nervous system (CNS), RGCs are relatively accessible and can be studied both anatomically and functionally to obtain information related to the state of neurons, including in patients with AD. \[[@pone.0236568.ref036]\] The properties of RGCs are similar in many ways to those of brain neurons such that anomalies in these cells can be related to brain dysfunction. In patients with AD both optic nerve degeneration and a loss of ganglion cells have been demonstrated. \[[@pone.0236568.ref037]--[@pone.0236568.ref039]\]

The pattern electroretinogram (PERG) is an electrophysiological test used to assess RGCs function. \[[@pone.0236568.ref040],[@pone.0236568.ref041]\] Although developed for the early diagnosis of glaucoma, its utility in neurological diseases, including multiple sclerosis, \[[@pone.0236568.ref042]\] AD \[[@pone.0236568.ref023], [@pone.0236568.ref043]--[@pone.0236568.ref045]\] and Parkinson's disease, \[[@pone.0236568.ref046]\] all of which are characterized by inflammation, neurotransmission anomalies, and neurodegeneration, has also been demonstrated. PERG can provide useful diagnostic, prognostic and follow-up information on these diseases.

A specific form of PERG is steady-state PERG (SS-PERG), in which a fast (steady-state) stimulus generates a sinusoidal response that can be analyzed by Fourier transform. This allows the isolation of a second harmonic whose amplitude and phase delay can be evaluated. The PERG amplitude is related to the number of surviving neurons, and the PERG phase delay to synaptic dysfunctions of living neurons. \[[@pone.0236568.ref047]\] Synaptic damage and remodeling of the RGCs dendritic tree have also been histologically demonstrated in mouse models of glaucoma. \[[@pone.0236568.ref048],[@pone.0236568.ref049]\] However, while a reduced amplitude is observed in patients with glaucoma and in those with ocular hypertension, \[[@pone.0236568.ref050]--[@pone.0236568.ref052]\] it is also a feature of conditions not related to glaucoma, such as cataract and myopia. \[[@pone.0236568.ref053]--[@pone.0236568.ref055]\] To overcome the limits of SS-PERG, a new test, the re-test PERG (RE-PERG), was recently introduced for the more accurate diagnosis of glaucoma. It is based on five consecutive SS-PERG stimulations without pause and evaluates the individual-intrinsic within-test phase variability of the second harmonic, rather than strictly the amplitude. Phase variability was shown to be very low in healthy controls but the standard deviation of the phase is higher in glaucoma patients. \[[@pone.0236568.ref056]\] Moreover, unlike the amplitude, phase variability is not influenced by optical media opacities and myopia. \[[@pone.0236568.ref057],[@pone.0236568.ref058]\] Second-level imaging-based tests for the diagnosis of AD and VD are often expensive and not always available, especially in rural hospitals, such that diagnostic tools based on biomarkers able to distinguish among the various types of dementia are needed. RE-PERG uses high temporal frequency stimuli able to evoke a response of the M system. A higher phase variability is related to RGCs dysfunction, which precedes ganglion cells loss. Thus, the current research evaluated the ability of RE-PERG to detect anomalies in the primary inner retinal bioelectric function of M-cells in patients with early-onset AD compared to those with VD and in NC.

Materials and methods {#sec006}
=====================

From September 1st to December 15th 2018, 52 consecutive patients (33 with MCI and 19 age-matched, healthy controls were finally enrolled in this study. All patients were recruited at the Alzheimer Evaluation Units of the Brindisi Social Health District, Brindisi, Italy. Neurologic exclusion criteria were: neurological/psychiatric conditions other than mild AD and VD, antidepressant-antipsychotic medication, history of malignancy, head trauma or stroke, drug abuse or addiction and metabolic or endocrine anomalies.

Ophthalmic exclusion criteria were: diabetes even in the absence of retinopathy, \[[@pone.0236568.ref059]\] ocular hypertension and glaucoma as diagnosed by the EGS guidelines, \[[@pone.0236568.ref060]\] congenital optic nerve head anomalies, retinopathy or any other ocular or general condition or therapy that might influence visual function, a best corrected visual acuity \<20/40 (Snellen acuity), spherical refraction \>±5.0 D, cylinder correction \>±2.0 D and optic media opacities. The healthy control (HC) group consisted of age- and sex-matched healthy individuals with no evidence of dementia as reported by the participant or his/her family.

Assessment of cognitive function {#sec007}
--------------------------------

In the neuropsychological evaluation, cognitive function was assessed using MMSE, a simple screening test that measures global cognitive function \[[@pone.0236568.ref061]\] by assessing orientation, memory, concentration, language, and design capacity. The same experienced examiner administered the test. The MMSE total score ranges between 0 and 30, with lower scores indicating a poorer cognitive ability. \[[@pone.0236568.ref062]\] Scores ≥28 points indicate normal cognition and \<28 points mild (24--27 points), moderate (10--23 points) or severe (≤9 points) cognitive impairment. A score of ≤9 points is considered to be almost diagnostic of dementia. \[[@pone.0236568.ref063]\]

All patients underwent structural MRI. AD and VD were diagnosed according to international consensus criteria. \[[@pone.0236568.ref064]\]

Ophthalmic examination {#sec008}
----------------------

Each participant underwent a comprehensive ophthalmic evaluation, including a review of medical history, best-corrected visual acuity testing, IOP measurement by Goldmann applanation tonometry, ultrasound pachymetry (Pachmate GH55 DGH Technology, Inc. Exton PA, USA), slit-lamp biomicroscopy, gonioscopy, and dilated fundus examination with a 78 lens. The criteria for the clinical and instrumental ophthalmic evaluation were the same as used in previous studies. \[[@pone.0236568.ref056]--[@pone.0236568.ref058]\]

Standard Automated Perimetry (SAP) {#sec009}
----------------------------------

The visual field was assessed using a Humphrey field analyzer, model 745i II (Carl Zeiss Meditec, Germany) and the 24--2 SITA standard strategy. Near addition was added to the refractive correction value. If fixation losses were \>20% and false-positive or false negative results \>15%, the test was repeated. At least two SAPs were performed to ensure reliable results and minimize the effect of learning. \[[@pone.0236568.ref065]\]

Spectral-domain Optical Coherence Tomography (OCT) {#sec010}
--------------------------------------------------

Peripapillary retinal nerve fiber layer (RNFL) and ganglion cell complex (GCC) thicknesses were assessed using a Zeiss Cirrus HD OCT-500 (software version 7.0.1.290, Carl Zeiss Meditec, Dublin, CA). The protocol's 200 × 200 optic disc cube was used to perform a circular scan 3.46 mm in diameter. The scan was automatically targeted around the optic disc to provide the RNFL thickness of the four quadrants at positions corresponding to each of the 12 hours of the clock. The protocol's 512 × 128 macular cube was used to measure macular thickness.

The same experienced technician performed all the OCTs. Only images with a quality score of at least 7/10 were used. Three consecutive scans of the optic disc and macular region were acquired and analyzed for each eye. The results of the RNFL and GCC measurements were averaged using the data from each of the three scans.

Pattern electroretinogram {#sec011}
-------------------------

RE-PERG was recorded using a commercial instrument (RETIMAX Advanced ver. 4.3 CSO Florence, Italy) and a method similar to that employed in the PERGLA paradigm, \[[@pone.0236568.ref066]\] with a few minor changes made by our laboratories. Specifically, we used a stimulus of horizontal bars with a spatial frequency of 1.7 cycles/degree---based on the results of previous studies showing the high sensitivity of this method in detecting RGCs dysfunction in early glaucoma \[[@pone.0236568.ref067],[@pone.0236568.ref068]\]---and modulated in counter phase at 15 reversals/s. The stimulus was electronically generated on a high-resolution ionized-gas electrically charged plasma display (contrast: 90% luminance: 80 cd/m^2^; field size: 24° \[width\] × 24° \[height\]).

The pupils of the patients or NC were 3--4 mm, undilated, and an appropriate correction was made for the working distance (57 cm). The signals were recorded from a 9-mm Ag/AgCl skin electrode placed on the lower eyelid. A similar electrode placed on the lid of the non-stimulated eye was used as a reference, as described in other studies. The impedance was maintained below 5 K. The responses were amplified (gain of 100,000), filtered (bandwidth: 130 Hz) and sampled with a resolution of 12 bits. The analysis time was equal to the period of the stimulus (133 ms).

An average of 650 PERG events (5 consecutive blocks of 130 events) for RE-PERG was calculated, with the automatic rejection of artifacts. The data were then exported to a text file and the mean amplitude (μV) and phase (πrad) of the 2nd harmonic were analyzed by Fourier transform.

The repeatability of the phase of the second harmonic was calculated as the standard deviation of the phase (SDPh). The repeatability of the amplitude (Amp) was not considered, because of a habituation effect. \[[@pone.0236568.ref069]\] The noise level arising from recording a response to an occluded stimulus was ≤0.087 ± 0.03 μV in both NC and patients. Figs [1](#pone.0236568.g001){ref-type="fig"}--[3](#pone.0236568.g003){ref-type="fig"} show examples of a block of five events in NC and in VD and AD patients. The PERG Amp and PERG SDph values are highlighted. In our laboratory, a PERG Amp value \<1.5 μv and PERG SDph values \>0.15 SD are considered to indicated pathology. The study was double blind in its design and all RE-PERGs were conducted by the same operator (A. Mavilio).

![](pone.0236568.g001){#pone.0236568.g001}
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![](pone.0236568.g003){#pone.0236568.g003}

Statistical analyses were performed using Medcalc® 18.11.3. Because of the high correlation of the responses of the two eyes of the same person, only the data from one randomly chosen eye was included in the analysis. \[[@pone.0236568.ref070]\]

The distribution of the data was tested for normality using the Shapiro--Wilk test, and a t test was used to determine the differences between two independent groups. Comparisons of more than two independent groups were performed using a one-way ANOVA with post-hoc analyses based on the Scheffe method. The relationships between the electrophysiological values and the SAP, peripapillary RNFL thickness and GCC thickness values were calculated using Pearson's correlation tests. A chi-squared test was used to compare the groups with respect to the categorical variables (sex). A p value \< 0.05 was considered to indicate statistical significance.

The Ethics Committee of the Brindisi Social Health District approved the study, and the study protocol adhered to the tenets of the Declaration of Helsinki. Written informed consent was obtained from each participant after administration of the University of California, San Diego Brief Assessment of Capacity to Consent (UBACC). \[[@pone.0236568.ref071]\]

Results {#sec012}
=======

The study population consisted of Italians with an education level equal to that of the 8th grade in the USA. All participants lived in Apulia at the time of their enrollment in the study, between 2017 and 2018. For some patients, the family doctor had requested a neuropsychological evaluation for suspected deterioration or dementia, based on cognitive-memory loss reported by the patients; for others, a neurological examination was requested by a neurologist for various reasons, including suspicion of dementia.

Initially, 58 patients were enrolled. However, because of unreliable visual field examinations or poor-quality OCT images, 6 were excluded (4 from the AD group and 2 from the VD group), leaving 52 patients in the study.

The 17 patients in the AD group (5 males and 12 females) ranged in age between 58 and 81 years. Most were retired and came to the visit with a caregiver (usually a family member). Some had active interests, but others did not.

The 16 age-matched patients in the VD group (9 males and 7 females) had not been diagnosed with AD.

The 19 members of the HC group (12 males and 7 females) were also age-matched with the patients. Demographic and other data of the study participants are summarized in [Table 1](#pone.0236568.t001){ref-type="table"}. The results of the statistical analyses are reported in [Table 2](#pone.0236568.t002){ref-type="table"}. There was no difference between groups with respect to age, mean deviation, pattern standard deviation (PSD), RNFL and GCC, as determined in an ANOVA. AD patients had a slight significant reduction in the PERG Amp (1.33±0.28 vs 1.67±0.16, p = 0.01) value compared to NC whereas the difference in the PERG SDph was highly significant between AD and VD patients (0.32±0.91 vs 0.12±0.04, p\<0.001) and between AD patients and NC (0.32±0.91 vs 0.12±0.03, p\<0.001) (Figs [4](#pone.0236568.g004){ref-type="fig"} and [5](#pone.0236568.g005){ref-type="fig"}).
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###### Demographics and specific data.

![](pone.0236568.t001){#pone.0236568.t001g}

  No   Type   gender   age, years   PERG SDPh   PERG Amp (μV)   MD (dB)   PSD (dB)   RNFL (μm)   GCC (μm)   MMSE
  ---- ------ -------- ------------ ----------- --------------- --------- ---------- ----------- ---------- ------
  1    VD     m        68           0.07        1.09            -1.69     1.54       88          76         25
  2    VD     m        57           0.12        1.89            -0.5      1.3        85          90         24
  3    VD     m        75           0.1         1.55            -1        1          94          81         25
  4    VD     m        72           0.15        1.47            1.46      1.4        90          77         27
  5    VD     m        64           0.09        1.44            1.44      0.8        85          72         28
  6    VD     f        66           0.15        1.6             -0.97     1          93          67         28
  7    VD     f        76           0.1         1.72            0.63      1.2        77          73         27
  8    VD     m        68           0.15        1.77            -0.97     1          93          67         27
  9    VD     f        80           0.11        1.42            1.01      1.4        95          92         26
  10   VD     f        62           0.06        1.55            0.77      0.74       96          82         28
  11   VD     f        67           0.23        1.53            0.85      1.02       92          80         27
  12   VD     m        84           0.17        1.42            0.93      1.24       81          79         26
  13   VD     m        75           0.12        1.55            0.47      0.94       90          77         26
  14   VD     m        79           0.14        1.75            1.01      0.87       94          80         18
  15   VD     f        72           0.14        1.7             0.88      1.5        94          90         22
  16   VD     f        67           0.05        2.1             -0.04     2.2        99          81         18
  17   AD     f        69           0.2         1.21            0.04      1.17       93          77         19
  18   AD     m        81           0.61        1               -0.43     1.47       87          72         27
  19   AD     f        74           0.15        1.34            0.89      1.34       84          77         24
  20   AD     f        60           0.07        1.5             -1.29     2.05       98          84         23
  21   AD     f        81           0.14        1.28            -0.78     1.28       81          77         28
  22   AD     m        66           0.48        1.16            -0.68     1.9        76          74         24
  23   AD     f        70           0.22        1.67            0.47      1.37       97          82         24
  24   AD     f        58           0.18        1.82            0.71      1.39       106         92         24
  25   AD     f        78           0.39        0.93            1.51      1.43       88          80         24
  26   AD     m        81           0.47        1.57            1.51      1.43       93          72         23
  27   AD     f        67           0.11        1.57            0.23      1.8        81          77         21
  28   AD     m        72           0.25        1.32            0.5       1.8        70          55         22
  29   AD     m        77           0.66        0.84            -0.75     1.22       82          76         25
  30   AD     f        79           0.58        1.11            1.34      0.97       80          65         28
  31   AD     f        60           0.3         1.1             0.8       1.12       77          75         29
  32   AD     f        76           0.14        1.52            -0.33     1.12       80          81         28
  33   AD     f        70           0.46        1.66            1.15      1.1        87          80         28
  34   NC     m        74           0.09        1.62            -0.4      0.8        88          72         28
  35   NC     m        74           0.13        1.78            -0.5      1.3        74          64         27
  36   NC     m        78           0.1         1.46            -1.01     1.2        88          70         29
  37   NC     m        68           0.12        1.65            2         1.5        104         91         27
  38   NC     m        70           0.11        1.58            1.3       1.55       101         91         26
  39   NC     f        74           0.12        1.79            1.1       0.88       87          71         27
  40   NC     m        70           0.1         1.71            -0.97     1          95          76         28
  41   NC     m        65           0.1         1.5             0.63      1.2        96          83         27
  42   NC     f        60           0.1         1.81            1.01      0.87       80          80         25
  43   NC     f        64           0.08        1.59            0.85      1.02       93          87         26
  44   NC     m        65           0.1         2.14            -0.23     1.1        79          70         28
  45   NC     m        60           0.11        1.51            -2.1      1.53       99          90         28
  46   NC     m        68           0.16        1.53            0.93      1.46       84          80         29
  47   NC     m        66           0.1         1.69            1.01      1.4        88          74         30
  48   NC     m        77           0.16        1.75            1.81      1.41       82          80         28
  49   NC     f        86           0.1         1.65            -0.5      1.3        92          86         25
  50   NC     f        62           0.15        1.5             -0.45     1.34       70          87         25
  51   NC     m        66           0.2         1.75            1         1.4        100         90         27
  52   NC     m        66           0.17        1.76            0.4       1.5        99          90         25

Mean Deviation (MD) Pattern Standard Deviation (PSD), Retinal Nerve Fiber Layer Thickness (RNFL), ganglion cell complex (GCC), steady-state intrinsic phase variability (PERG SDph) steady-state PERG amplitude (PERG Amp), Mini-Mental State Examination (MMSE) in Early Alzheimer disease (AD), Vascular Dementia-related MCI (VD) and Normal Controls (NC)

10.1371/journal.pone.0236568.t002

###### Demographic and relevant ocular characteristic of study participants.

![](pone.0236568.t002){#pone.0236568.t002g}

                  AD (17)   VD (16)   NC (19)   P-value^®^                                        
  --------------- --------- --------- --------- ------------ ------- ------ ---------- ---------- ----------
  age             71.71     7.63      70.75     7.17         69.10   6.67   P = 0.72   P = 0.5    P = 0.44
  PERG Amp (μv)   1.33      0.28      1.59      0.23         1.67    0.16   P = 0.2    P = 0.26   P = 0.01
  PERG SDph       0.32      0.19      0.12      0.04         0.12    0.03   P\<0.001   P = 0.95   P\<0.001
  MD (db)         0.29      0.88      0.27      0.99         0.31    1.07   P = 0.5    P = 0.90   P = 0.31
  PSD (db)        1.41      0.31      1.20      0.37         1.25    0.24   P = 0.6    P = 0.24   P = 0.52
  GCC (μm)        76.23     7.96      79.00     7.39         80.63   8.60   P = 0.6    P = 0.24   P = 0.23
  RNFL (μm)       85.89     9.18      90.38     5.85         89.42   9.56   P = 0.1    P = 0.73   P = 0.77
  MMSE            24.76     2.84      25.12     3.20         27.10   1.49   P = 0.73   P = 0.02   P = 0.01

Mean Deviation (MD) Pattern Standard Deviation (PSD), Retinal Nerve Fiber Layer Thickness (RNFL), ganglion cell complex (GCC), steady-state intrinsic phase variability (PERG SDph) steady-state PERG amplitude (PERG Amp), Mini-Mental State Examination (MMSE) in Early Alzheimer disease (AD), Vascular Dementia-related MCI (VD) and Normal Controls (NC)

\*--One Way Analysis of Variance (Bonferroni corrected); \*\*---Chi-Square

The MMSE score was significantly lower in both AD and VD patients than in NC (P = 0.02; P = 0.01 respectively).

The results of the correlation analysis are reported in [Table 3](#pone.0236568.t003){ref-type="table"}.

10.1371/journal.pone.0236568.t003

###### Correlation table.
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                          age     MD (dB)   PSD (dB)   GCC (μm)   RNFL (μm)   PERG Amp (μV)   PERG SDPh   MMSE
  --------------- ------- ------- --------- ---------- ---------- ----------- --------------- ----------- --------
  age             CC              0.12      -0.09      -0.27      -0.17       -0.29           0.3         -0.02
  SL-P                    0.4     0.5       0.05       0.22       0.03        0.03            0.90        
  MD (db)         CC      0.12              -0.13      0.13       0.06        0.09            0.11        0.002
  SL-P            0.4             0.36      0.35       0.67       0.53        0.43            0.99        
  PSD (db)        CC      -0.09   -0.13                0.17       0.06        -0.07           0.07        -0.42
  SL-P            0.54    0.36              0.22       0.69       0.64        0.64            0.0018      
  GCC (μm)        CC      -0.27   0.13      0.17                  0.59        0.21            -0.27       -0.14
  SL-P            0.051   0.35    0.22                 \<0.0001   0.13        0.054           0.31        
  RNFL (μm)       CC      -0.17   0.06      0.06       0.59                   0.28            -0.24       -0.15
  SL-P            0.22    0.67    0.69      \<0.0001              0.04        0.08            0.29        
  PERG Amp (μv)   CC      -0.29   0.09      -0.07      0.21       0.28                        -0.6        -0.05
  SL-P            0.038   0.52    0.63      0.13       0.05                   \<0.0001        0.71        
  PERG SDPh       CC      0.3     0.11      0.07       -0.27      -0.24       -0.6                        -0.006
  SL-P            0.03    0.43    0.64      0.054      0.08       \<0.0001                    0.97        
  MMSE            CC      -0.02   0.002     -0.42      -0.14      -0.15       -0.05           -0.006       
  SL-P            0.91    0.99    0.0018    0.31       0.29       0.71        0.97                        

Pearson Correlation Coefficient (CC) and Significance Level P (SL-P) between Mean Deviation (MD) Pattern Standard Deviation (PSD), Retinal Nerve Fiber Layer Thickness (RNFL), ganglion cell complex (GCC), steady-state intrinsic phase variability (PERG SDph) steady-state PERG amplitude (PERG Amp) and Mini-Mental State Examination (MMSE) in all participants

There was a negative correlation between PERG Amp and age and between MMSE and PSD. Positive correlations were determined for PERG Amp and increasing PERG SDPh, for RNFL thinning and GCC thinning and for a reduction in PERG Amp and RNFL thinning.

Discussion {#sec013}
==========

The two most frequent causes of dementia worldwide are AD and VD, and their prevalence is expected to increase as populations age. Both diseases may be preceded by MCI, which is common in the elderly population but not necessarily associated with subsequent dementia. AD is associated especially with amnestic MCI, and VD with executive dysfunction and psychomotor slowness, \[[@pone.0236568.ref072]\] but psychometric evaluation findings alone cannot be used to discriminate VD from AD. Both AD and VD are accompanied by visual disturbances, due primarily to retinal degeneration and retrograde degeneration, respectively. The early diagnosis of AD may allow better disease management, including a delay of symptom occurrence. However, the most accurate tests for the diagnosis of AD are expensive or invasive. Consequently, there is a growing need for the detection of new, less-invasive and more cost-effective diagnostic testing.

In most AD patients, the visual association cortices are altered whereas the primary visual cortex is spared. \[[@pone.0236568.ref073]\] Involvement of other areas of the visual pathway is controversial: as in some patients alterations of stereopsis and contrast sensitivity have been reported even in those without evidence of plaques and neurofibrillary tangles. \[[@pone.0236568.ref074]\] Other studies have demonstrated an involvement of the magnocellular pathway (a visual pathway extending from the inner layers of the retina to the primary visual cortex) in the form of the deposition of a specific type of plaque in the lateral geniculate nucleus as well as in RGCs and their axons. \[[@pone.0236568.ref075]\] Based on these observations, an evaluation of the macular RGC layer may provide useful diagnostic information for patients with suspected AD. The RGC layer can be studied by imaging and electrophysiological tests, PERG and visual evoked potentials. \[[@pone.0236568.ref023],[@pone.0236568.ref076],[@pone.0236568.ref077]\] For example, ssPERG tests conducted in a mouse model of AD showed alterations in the amplitude of the second wave. \[[@pone.0236568.ref078]\] However, in ssPERG testing the studied parameter is usually the amplitude, but it can be influenced by causes not related to neurodegeneration, such as optic media opacities and myopia, whereas the phase is not. Thus, we developed a new test, RE-PERG, in which the variability of the phase is studied based on five consecutive ssPERG stimulations. In previous studies we showed that phase variability is higher in glaucoma patients and that it is not influenced by cataract or myopia. \[[@pone.0236568.ref057],[@pone.0236568.ref058]\] Since the neurodegeneration of RGCs shows similar features in glaucoma and AD, we examined the ability of RE-PERG to identify early-stage AD and to discriminate AD from VD on the basis of the different mechanisms of neurodegeneration. The results showed a slightly significant reduction in the PERG Amp value in AD patients vs. NC, but no difference between VD patients and NCs. However, the difference in the PERG SDPh in AD vs. VD patients and in AD versus NC patients was highly significant; therefore, PERG SDPh may be of value not only in detecting inner retinal dysfunction in AD, but also in distinguishing between AD and VD.

Correlation studies showed a negative correlation between PERG Amp and age, as expected due to the physiological loss of RGCs. The negative correlation between MMSE and PSD, that is, a worsening of the visual field related to a reduction in the MMSE score, may reflect the neurodegeneration occurring both in the retina and in the brain. The positive correlation between PERG Amp reduction and an increased PERG SDPh can be explained by a worsening of all parameters with disease progression, and that between RNFL and RGC thinning by the parallel degeneration of neuronal cell bodies and axons ([Table 3](#pone.0236568.t003){ref-type="table"}). The positive correlation between PERG Amp reduction and RNFL thinning indicates that the amplitude is related to the number of surviving RGCs.The findings of our study suggest that PERG SDph is a suitable parameter to detect early damage to magnocellular RGCs in AD patients. While the M system has been shown to respond to stimuli of high temporal frequency, a response by the P system cannot be excluded, also because the K and P visual streams were not specifically tested. However, there are fewer P cells and they tend to be scattered, such that the increased PERG SDph could be predominantly attributed to M dysfunction. Our finding is in agreement with other studies in which involvement of the M pathway was reported. \[[@pone.0236568.ref023]\]

As noted above, the phase variation is related to the synaptic loss and dendritic degeneration that may precede ganglion cell loss. \[[@pone.0236568.ref047]\] Such alterations have been described in early AD, but also in Parkinson's and Huntington's diseases. \[[@pone.0236568.ref079]\] Normal neuronal activity is accompanied by a high energy demand; \[[@pone.0236568.ref080]\] such that RE-PERG serves as a metabolic stress test able to show early damage to RGCs.

In glaucoma patients, functional and anatomical changes may be present in RGCs before any damage of the optic nerve is detectable. \[[@pone.0236568.ref052]\] Thus, in CNS diseases that share some features of the degeneration seen in glaucoma, the same may be true.

Our study may have been biased by several factors. First, the diagnosis of MCI was based exclusively on the MMSE, which cannot replace a full psychometric evaluation. Tests specific for AD include the Alzheimer\'s Disease Assessment Scale (ADAS-Cog), the Clinical Dementia Rating (CDR) score, and the Repeatable Battery for the Assessment of Neuropsycological Status (RBANS). In the diagnosis of VD, the Montreal Cognitive Assessment (MoCA) has a higher sensitivity and specificity than the MMSE. \[[@pone.0236568.ref081]\] However, our study was performed in a National Health Service setting, and MMSE is the only psychometric test available. Thus, it cannot be ruled out that a more specific evaluation would have led to a different definition of mental status and influenced our results.

Another possible source of bias was the small number of enrolled patients. Further studies with a larger cohort of patients are required to confirm our preliminary results.

Two issues emerge from this study. The first is the question whether the alteration in PERG SDPh is a sign of primary RGCs degeneration or related to transsynaptic degeneration in the visual cortex. In our opinion, the first hypothesis is more likely, as RGC thinning has been found both in prodromal and in preclinical AD as well as in patients without other signs of visual cortex involvement. \[[@pone.0236568.ref082],[@pone.0236568.ref083]\]

The second is the shared finding of an altered PERG SDph in both glaucoma and AD. AD and glaucoma have several common features. Epidemiological studies have shown that the prevalence of glaucoma in AD patients is about 25% vs. 5--6% in the non-AD population. \[[@pone.0236568.ref084],[@pone.0236568.ref085]\] Abnormal folded amyloid beta (Aɞ) and tau protein, typical findings in AD, have been demonstrated both in mouse models of glaucoma and in humans with the disease. \[[@pone.0236568.ref086],[@pone.0236568.ref087]\] In addition, several studies have shown OCT alterations typical of glaucoma, such as RNFL and RGC thinning, in patients with early and even preclinical AD, \[[@pone.0236568.ref088],[@pone.0236568.ref089]\] and visual field alterations detected in glaucoma, including arcuate defects, also occur in AD. \[[@pone.0236568.ref090]\] Finally, an enlarged cup-to-disc ratio of the optic nerve, the most typical feature of glaucoma, has also been detected in some, \[[@pone.0236568.ref091]--[@pone.0236568.ref093]\] but not all \[[@pone.0236568.ref094],[@pone.0236568.ref095]\] AD patients.

Recently, optical coherence tomography angiography (OCT-A) has been used to study AD. Bulut et al. reported a lower retinal vascular density (VD) and choroidal thickness \[[@pone.0236568.ref096]\] together with an enlargement of the foveal avascular zone (FAZ) in AD patients compared to NC. In a comparison of AD and primary open-angle glaucoma (POAG) patients, Zabel et al. found a larger FAZ and a reduced vascular density in the deep vascular plexus in the AD group \[[@pone.0236568.ref097]\] whereas in POAG patients reductions in the vascular density of the superficial vascular plexus and in radial peripapillary capillaries were detected. However, a reduced VD and FAZ enlargement have also been reported in normal-tension glaucoma (NTG). \[[@pone.0236568.ref098]\] In addition, an even larger FAZ occurs in progressed glaucoma (both NTG and POAG) \[[@pone.0236568.ref099]\] and in POAG patients with central visual field defects. \[[@pone.0236568.ref100]\] The FAZ is also variably influenced by glaucoma surgery. \[[@pone.0236568.ref101]\]

Finally, the reduced VD of the deep macular plexus, such as reported by Zabel et al. in AD patients, is also a feature of progressed NTG. \[[@pone.0236568.ref099]\] Thus, whether OCT-A findings comprise a specific biomarker of AD remains to be determined in further studies. Moreover, these studies also demonstrate that all of the tools used to diagnose glaucoma may be biased by the presence of AD. In the absence of an elevated intraocular pressure, i.e. in a patient with NTG, the differential diagnosis can be particularly challenging and AD has to be carefully ruled out.

Other causes of inner retinal dysfunction, detectable by electrophysiological tests, as stated before, are Multiple Sclerosis and Parkinson\'s disease; we didn\'t test RE-PERG in these diseases, but its alteration cannot be excluded. At the same way, it is also known that age-related visual conditions such as age itself, presbyopia and cataract can influence PERG. As for cataract, we showed reduced amplitude with small intrinsic variability of the phase in a RE-PERG pilot study,\[[@pone.0236568.ref057]\] but further studies are required also in the other above-mentioned conditions. Our results suggest that RE-PERG is a quick, easy to perform and non-invasive test able to detect RGC dysfunction in AD, but despite its promise its utility must be confirmed in other laboratories and in larger cohorts of patients.

10.1371/journal.pone.0236568.r001
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Dear Dr. Mavilio,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration by 2 Reviewers and an Academic Editor, all of the critiques of both Reviewers must be addressed in detail in a revision to determine publication status. If you are prepared to undertake the work required, I would be pleased to reconsider my decision, but revision of the original submission without directly addressing the critiques of the two Reviewers does not guarantee acceptance for publication in PLOS ONE. If the authors do not feel that the queries can be addressed, please consider submitting to another publication medium. A revised submission will be sent out for re-review. The authors are urged to have the manuscript given a hard copyedit for syntax and grammar.
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**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. 
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2\. Has the statistical analysis been performed appropriately and rigorously? 
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3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes
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4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.
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5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Introduction:

1\. Authors should explain in more detail what Alzheimer\'s disease is and how it differs from (VD) -related MCI, describe changes in the CNS, retina, and why eye biomarkers may be useful.

2\. How do we confirm the diagnosis of AD in sMRI?

MATERIALS AND METHODS:

1\. The authors described that neurologic exclusion criteria were: „neurological / psychiatric conditions other than mild AD\"- what about patients who had vascular dementia? After all, they were included in the study.

2\. Did all participants have an MRI? How on the basis of sMRI diagnosed and distinguish patients with AD and VD.

3\. The description of the statistics should be more detailed, paying attention to the tests used.

Results:

1\. „ANOVA analysis showed no difference between groups for age. MD. PSD RNFL and GCC."- errors in punctuation

2\. Please specify the number and characteristics of excluded subjects to reduce the selection bias.

Discussion:

1\. Epidemiology, diagnosis and pathogenesis should be included in the introduction (not in the discussion).

2\. Unfortunately, the most effective tests for the diagnosis of AD are expensive and invasive."- e.g. MRI is not an invasive test, therefore this sentence should be formulated more precisely

3\. \"Since the neurodegeneration of RGCs shows similar features in both glaucoma and AD, we performed this study in order to evaluate the ability of RE-PERG in the identification of the early stage of AD. \"- How can RE-PERG distinguish AD from glaucoma? Since the PERG test is used in glaucoma diagnosis why the authors did not compare glaucoma, AD and HC?

4\. The authors did not describe the limitations of their research

5\. MMSE may not be the best cognitive test with which to measure AD related cognitive impairment. This should be acknowledged and the limitations explored in the discussion.

6\. Why do the authors compare patients with VD to AD and NC if the problem is to distinguish AD from glaucoma? I think that vascular changes in the retina in AD patients should be mentioned (Bulut, M., Kurtuluş, F., Gözkaya, O., Erol, M. K., Cengiz, A., Akıdan, M., & Yaman, A. (2018). Evaluation of optical coherence tomography angiographic findings in Alzheimer's type dementia. British Journal of Ophthalmology, 102(2), 233-237.) and describe differences in microvascularization between AD, POAG and NC (Zabel, P., Kaluzny, J. J., Wilkosc-Debczynska, M., Gebska-Toloczko, M., Suwala, K., Zabel, K., \... & Araszkiewicz, A. (2019). Comparison of Retinal Microvasculature in Patients With Alzheimer\'s Disease and Primary Open-Angle Glaucoma by Optical Coherence Tomography Angiography. Investigative ophthalmology & visual science, 60(10), 3447-3455.)

References:

1\. Kamila K., Wojciech L., Andrzej P. Pattern electroretinogram (PERG) and pattern visual evoked potential (PVEP) in the early stages of Alzheimer's disease Doc Ophthalmol. 2010 435 Oct; 121(2): 111--121."- these are not the author\'s\' last names

Reviewer \#2: Manuscript n.: PONE-D-19-31892

TITLE: RE-PERG in early-onset Alzheimer's disease. A double-blind electrophysiological pilot study.

Article Type: Research Article.

In this study, the Authors investigate the ability RE-PERG (retest PERG) in detection inner retinal bioelectric function abnormalities in patients with early-onset Alzheimer Disease (AD). They investigated a series of pt. (17 pt.) with AD and report mean RE-PERG amplitude significantly lower and phase of 2nd harmonic (PERG SDPh) higher in AD pts. compared with controls. Moreover, they affirm that RE-PERG can be useful to identify early AD stages and that changes may be imputable to magnocellular pathway dysfunction not present in other conditions, like vascular dementia and conclude that RE-PERG could be a new promising biomarker of neurodegenerative disease.

The study is well conducted and written, results are clear, sound well and could be interesting for the readership of the journal, even if not at all new (see previous paper on the same field reported in references).

The manuscript has some issues needed to be addressed.

Major criticism are:

\- First, the AA address the magnocellular pathway (M pathway), but it should be kept in mind that there are other pathway subsystems (Parvo-, P and Konio-cellular, K subsystem; see Paper of Livingstone, Porciatti, van Essen etc. on this topic). The AA should add some information concerning these subsystems and their propriety. In fact whereas color information is processed mainly by the P system, luminance by both P and M subsystem. Moreover, the stimulus employed by the AA is not selective for the Magno and result could be aspecific. The AA should add some informations on visual pathways subsystem and property.

\- Second the AA to exclude a bias in their study should exclude involvement of other subsystem before to affirm an exclusive magnocellular dysfunction in their conclusions. Please clarify.

\- Third, How can the AA exclude that a lower RE-PERG and a higher SDPh RE-PERG are not an aspecific changes

Keywords: I suggest add visual pathway subsystem.

Abstract: modify according the above criticisms.

Introduction: see major criticisms.

In line 89 they affirm that " ... this parameter is not influenced by optical ..."; I suggest "scarcely influenced by refraction "

Materials and methods: -

Discussion and Concluding remarks: they have to be rewritten following the above suggestions and comments.

References: there are only few typing mistaken and two reference in my opinion seems the same (n. 14 and 56): check.
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Stephen D. Ginsberg, Ph.D.

Section Editor
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\"The Institutional Review Board and Ethics Committee of the institute approved the study, and the study protocol adhered to the tenets of the Declaration of Helsinki. Written informed consent was obtained from each participating patient.\"
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4\) Thank you for stating the following financial disclosure:

 \[NO\].

Please provide an amended Funding Statement that declares \*all\* the funding or sources of support received during this specific study (whether external or internal to your organization) as detailed online in our guide for authors at <http://journals.plos.org/plosone/s/submit-now>.  

Please state what role the funders took in the study.  If any authors received a salary from any of your funders, please state which authors and which funder. If the funders had no role, please state: \"The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.\"

\* Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

5\) Thank you for stating the following in your Competing Interests section: 

\[NO\].

i\) Please complete your Competing Interests on the online submission form to state any Competing Interests. If you have no competing interests, please state \"The authors have declared that no competing interests exist.\", as detailed online in our guide for authors at <http://journals.plos.org/plosone/s/submit-now>
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Dear Editor,

Enclosed you find the updated version of our manuscript, which has been widely revised according to your reviewers\' criticisms. The manuscript has also been corrected by an English medical editor.

The Authors have declared that no competing interest exist.

The Authors received no specific funding for this work

Best regards

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Introduction:

1\. Authors should explain in more detail what Alzheimer\'s disease is and how it differs from (VD) -related MCI, describe changes in the CNS, retina, and why eye biomarkers may be useful.

DONE: please, see new introduction

2\. How do we confirm the diagnosis of AD in sMRI?

DONE: please, see introduction, lines 93-95

MATERIALS AND METHODS:

1\. The authors described that neurologic exclusion criteria were: „neurological / psychiatric conditions other than mild AD\"- what about patients who had vascular dementia? After all, they were included in the study.

DONE: line 149

2\. Did all participants have an MRI? How on the basis of sMRI diagnosed and distinguish patients with AD and VD.

DONE: please, see introduction and lines 165-166

3\. The description of the statistics should be more detailed, paying attention to the tests used.

DONE: lines 219-228

Results:

1\. „ANOVA analysis showed no difference between groups for age. MD. PSD RNFL and GCC."- errors in punctuation

DONE: lines 249-251

2\. Please specify the number and characteristics of excluded subjects to reduce the selection bias.

DONE: lines 239-241

Discussion:

1\. Epidemiology, diagnosis and pathogenesis should be included in the introduction (not in the discussion).

DONE: please, see new introduction

2\. Unfortunately, the most effective tests for the diagnosis of AD are expensive and invasive."- e.g. MRI is not an invasive test, therefore this sentence should be formulated more precisely

DONE: please, see lines 269-270

3\. \"Since the neurodegeneration of RGCs shows similar features in both glaucoma and AD, we performed this study in order to evaluate the ability of RE-PERG in the identification of the early stage of AD. \"- How can RE-PERG distinguish AD from glaucoma? Since the PERG test is used in glaucoma diagnosis why the authors did not compare glaucoma, AD and HC?

This is not the aim of our study. This matter is developed in the discussion section; currently no diagnostic test used for glaucoma (i.e. OCT of the optic nerve, visual field examination, electrophysiological tests) can distinguish between glaucoma and AD, this is true also for REPERG. According to some works the only difference seems to be the appareance of the optic nerve (which should show cupping in glaucoma but not in AD) even if according to other authors a similar cupping can be observed also in AD. As we state in the discussion section, this situation can make it difficult to distinguish between glaucoma and AD, especially when a raise of intraocular pressure is not detectable, that is, in case of normal-tension glaucoma suspect.

4\. The authors did not describe the limitations of their research

DONE: please, see lines 317-325

5\. MMSE may not be the best cognitive test with which to measure AD related cognitive impairment. This should be acknowledged and the limitations explored in the discussion.

DONE: please, see lines 317-325

6\. Why do the authors compare patients with VD to AD and NC if the problem is to distinguish AD from glaucoma? I think that vascular changes in the retina in AD patients should be mentioned (Bulut, M., Kurtuluş, F., Gözkaya, O., Erol, M. K., Cengiz, A., Akıdan, M., & Yaman, A. (2018). Evaluation of optical coherence tomography angiographic findings in Alzheimer's type dementia. British Journal of Ophthalmology, 102(2), 233-237.) and describe differences in microvascularization between AD, POAG and NC (Zabel, P., Kaluzny, J. J., Wilkosc-Debczynska, M., Gebska-Toloczko, M., Suwala, K., Zabel, K., \... & Araszkiewicz, A. (2019). Comparison of Retinal Microvasculature in Patients With Alzheimer\'s Disease and Primary Open-Angle Glaucoma by Optical Coherence Tomography Angiography. Investigative ophthalmology & visual science, 60(10), 3447-3455.)

DONE: please see our answer to point 3. As for OCT-A, see lines 342-351

References:

1\. Kamila K., Wojciech L., Andrzej P. Pattern electroretinogram (PERG) and pattern visual evoked potential (PVEP) in the early stages of Alzheimer's disease Doc Ophthalmol. 2010 435 Oct; 121(2): 111--121."- these are not the author\'s\' last names

DONE

Reviewer \#2: Manuscript n.: PONE-D-19-31892

TITLE: RE-PERG in early-onset Alzheimer's disease. A double-blind electrophysiological pilot study.

Article Type: Research Article.

In this study, the Authors investigate the ability RE-PERG (retest PERG) in detection inner retinal bioelectric function abnormalities in patients with early-onset Alzheimer Disease (AD). They investigated a series of pt. (17 pt.) with AD and report mean RE-PERG amplitude significantly lower and phase of 2nd harmonic (PERG SDPh) higher in AD pts. compared with controls. Moreover, they affirm that RE-PERG can be useful to identify early AD stages and that changes may be imputable to magnocellular pathway dysfunction not present in other conditions, like vascular dementia and conclude that RE-PERG could be a new promising biomarker of neurodegenerative disease.

The study is well conducted and written, results are clear, sound well and could be interesting for the readership of the journal, even if not at all new (see previous paper on the same field reported in references).

The manuscript has some issues needed to be addressed.

Major criticism are:

\- First, the AA address the magnocellular pathway (M pathway), but it should be kept in mind that there are other pathway subsystems (Parvo-, P and Konio-cellular, K subsystem; see Paper of Livingstone, Porciatti, van Essen etc. on this topic). The AA should add some information concerning these subsystems and their propriety. In fact whereas color information is processed mainly by the P system, luminance by both P and M subsystem. Moreover, the stimulus employed by the AA is not selective for the Magno and result could be aspecific. The AA should add some informations on visual pathways subsystem and property.

DONE: please, see new introduction (lines 71-83)

\- Second the AA to exclude a bias in their study should exclude involvement of other subsystem before to affirm an exclusive magnocellular dysfunction in their conclusions. Please clarify.

Please please, see new introduction and comments (lines 77-80)

\- Third, How can the AA exclude that a lower RE-PERG and a higher SDPh RE-PERG are not an aspecific changes

By means of exclusion criteria

Keywords: I suggest add visual pathway subsystem.

DONE

Abstract: modify according the above criticisms.

DONE: please, see lines 317-325

Introduction: see major criticisms.

In line 89 they affirm that " ... this parameter is not influenced by optical ..."; I suggest "scarcely influenced by refraction "

Our statement is based on exclusion criteria and on our previous works (ref 56-58)

Materials and methods: -

Discussion and Concluding remarks: they have to be rewritten following the above suggestions and comments.

DONE

References: there are only few typing mistaken and two reference in my opinion seems the same (n. 14 and 56): check.

DONE
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